Every Form 4 that Chemed Corporation (CHE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CHE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHE filings page.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock on September 18, 2026 in an open-market or private transaction at a weighted average price of $501.40 per share, with individual trade prices ranging from $501.00 to $502.05. Following this sale, he directly holds 68,418 shares of Chemed stock, and no Rule 10b5-1 trading plan is indicated.
CHEMED CORP (CHE) executive vice president Spencer S. Lee reported selling 1,000 shares of CHEMED CORP capital stock on August 21, 2026 in an open-market or private transaction at a price of $541.04 per share. After this sale, Lee directly holds 13,912 shares of CHEMED CORP capital stock.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Chemed capital stock on 2026-08-21 in an open market or private transaction. The weighted average sale price was reported as $541.16 per share, with individual trade prices ranging from $539.62 to $542.53. After this transaction, McNamara directly held 70,418 shares of Chemed capital stock. The company notes that full trade-by-trade pricing details are available upon request.
Chemed Corp executive Brian C. Judkins, VP and Chief Legal Officer, exercised stock options covering 6,786 shares of capital stock at an exercise price of $445.35 per share. The options, which vest in three equal annual installments beginning 10/28/2022, now leave him with 31,281 option-based shares outstanding. To fund the option purchase and related tax obligation, 5,878 shares of capital stock were delivered or withheld at $548.96 per share.
Chemed Corp executive Joel L. Wherley, CEO of Vitas Healthcare, exercised stock options for 2599.0000 shares of capital stock at $445.3500 per share on 2026-08-05. The options, vesting in three equal annual installments commencing 10/28/2022, were fully exercised, leaving him with 30220.0000 direct shares. In a related transaction, 2270.0000 shares of capital stock at $542.6200 per share were withheld to cover the purchase price and tax obligation on the option exercise.
Chemed Corp president and CEO Kevin J. McNamara reported an option exercise and related share dispositions. He exercised stock options for 2,001 shares at $445.35 and sold 2,000 shares of capital stock at a weighted average $539.51. An additional 19,802 shares were withheld to pay the option purchase price and related tax obligations. After the derivative transaction, he directly held 264,158 stock options.
Chemed Corp director Patrick P. Grace reported a sale of 190 shares of Capital Stock on 2026-07-31 at $532.00 per share in an open market or private transaction. After this sale, he directly owns 3,533 shares of Chemed stock. The filing does not indicate that this trade was made under a Rule 10b5-1 trading plan.
Chemed Corp director Andrea R. Lindell reported an open-market sale of 1,347 shares of Capital Stock at $447.33 per share. After this transaction, Lindell directly holds 4,578 shares. This filing reflects a discretionary sale by a board member rather than a compensation-related award.
Chemed Corp director George J. Walsh III reported an open-market sale of company stock. He sold 500 shares of Chemed capital stock at a price of $437.83 per share. After this sale, he continues to hold 3,209 shares directly and 434 shares indirectly through his spouse.
WALSH GEORGE J III reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director WALSH GEORGE J III reported a stock award of 386 shares of Capital Stock. The shares were granted at a reported price of $440.77 per share as a compensation-related award. Following this grant, he directly holds 3,709 shares. A separate entry shows indirect ownership of 434 shares held by his spouse, reflecting family holdings rather than a new market trade.
CHEMED CORP director John Meredith Mount Jr. reported a compensation-related stock award of capital stock. He received 386 shares on May 18, 2026, described as an award of stock in the footnotes. The grant was valued at $440.77 per share for reporting purposes. After this award, his direct holdings increased to 1,316 shares of Chemed capital stock. This is a non-derivative, grant/award acquisition rather than an open-market purchase or sale.
CHEMED CORP director Eileen P. McCarthy received an award of 386 shares of Capital Stock as compensation. The shares were granted on May 18, 2026 at a value of $440.77 per share, described as an award of stock.
Following this non-market acquisition, McCarthy directly holds 1,241 shares of CHEMED CORP Capital Stock. This transaction reflects an equity compensation grant rather than an open-market purchase, increasing her direct ownership stake in the company.
LINDELL ANDREA R reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Andrea R. Lindell received an award of 386 shares of Capital Stock on May 18, 2026, valued at $440.77 per share. This was a stock grant rather than an open-market purchase. After the award, she directly holds 5,925 shares.
Heaney Christopher J reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Christopher J. Heaney received an equity award of 386 shares of Capital Stock. The award, described as an “Award of stock,” was granted on May 18, 2026 at a price of $440.77 per share. Following this grant, Heaney directly owns 2,775 shares of Chemed capital stock. This is a compensation-related stock award rather than an open-market purchase or sale.
GRACE PATRICK P reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Patrick P. Grace received an award of 386 shares of Capital Stock on May 18, 2026. The shares were valued at $440.77 per share in the Form 4. After this stock award, Grace held a total of 3,723 shares directly.
DeLyons Ron reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Ron DeLyons received an award of 386 shares of Capital Stock on May 18, 2026. The shares were valued at $440.77 per share for the transaction. This was a grant or award, not an open-market purchase, and increased his direct holdings to 2,052 shares after the transaction.
CHEMED CORP director Patrick P. Grace sold shares in an open-market trade. On this transaction date, he sold 60 shares of Chemed Capital Stock at an average price of $425.78 per share. After the sale, he directly owned 3,337 shares, so the transaction represented only a small portion of his holdings.
Chemed Corporation president and CEO Kevin J. McNamara reported an open-market sale of 2,000 shares of Chemed Capital Stock. The weighted average sale price was $421.13 per share, with individual trades executed between $418.99 and $424.95. Following this transaction, McNamara directly holds 90,219 shares of Chemed stock.
Chemed Corporation president and CEO Kevin J. McNamara completed an open-market sale of company Capital Stock. On March 27, 2026, he sold 1,500 shares at a weighted average price of $369.37 per share in multiple trades.
The shares were sold at prices ranging from $365.76 to $373.24. Following this transaction, McNamara directly holds 92,219 shares of Chemed stock.
CHEMED CORP president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock in an open-market transaction at a weighted average price of $403.18 per share. Following this sale, he directly holds 93,719 shares. The trade was executed through multiple transactions at prices between $399.31 and $404.68.
Chemed Corp executive vice president Spencer S. Lee reported PSU vesting, share issuance, tax withholding, and a new equity award. On February 13, 2026, 499 shares of Chemed capital stock were acquired through derivative exercises at $469.56 per share, with 154 shares withheld to cover taxes, leaving 14,912 shares of capital stock held directly.
Two tranches of 402 performance stock units each were exercised at $0, with 1,966 and 1,564 PSUs remaining after the respective transactions. Lee also received a new grant of 960 PSUs, bringing direct PSU holdings to 2,524. One PSU award tied to cumulative adjusted EPS paid out at 124.1% of target based on $67.67 performance versus a $66.46 maximum threshold, while a separate PSU award tied to relative total shareholder return paid out at 0% of target.
Chemed vice president and director Thomas C. Hutton reported equity compensation activity, not open-market trading. On February 13, 2026, he exercised performance stock units (PSUs) into 199 shares of capital stock at $469.56 per share and had 72 shares withheld to cover tax obligations tied to vesting.
The PSUs that vested were based on Chemed’s cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, producing an award above target. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0% of target. Hutton also received a new grant of 374 PSUs that can vest over the 2026–2028 performance period.
Chemed Corp CEO Joel L. Wherley reported equity compensation activity tied to performance stock units on February 13, 2026. He acquired 273 shares of capital stock through the exercise of PSUs at an exercise price of $469.56 per share and had 852 shares of capital stock directly owned afterward. The company’s cumulative adjusted earnings per share of $67.67 for the 2023–2025 period exceeded the $66.46 maximum payout threshold, resulting in a PSU payout of 123% of target, or 124.1% including dividend reinvestment. A separate PSU award based on relative total shareholder return for the same period paid out at 0% of target.
Chemed Corporation’s VP & Chief Financial Officer Michael D. Witzeman reported equity compensation activity tied to performance stock units (PSUs). On 02/13/2026, 413 shares of capital stock were issued at $469.56 per share from PSU vesting, with 120 shares withheld to cover taxes, leaving 5,953 shares directly owned.
The PSU vesting was driven by performance from January 1, 2023 through December 31, 2025. Cumulative adjusted EPS of $67.67 exceeded the maximum payout threshold of $66.46, producing an award at 123% of target, or 124.1% including dividend reinvestment. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0%, including dividends. Witzeman also received a grant of 1,394 new PSUs that can each convert into one share of capital stock based on performance from January 1, 2026 to December 31, 2028, with final performance determined by March 15, 2029.
Chemed Corp director and president/CEO Kevin J. McNamara reported equity compensation activity involving performance stock units and company shares. On February 13, 2026, performance stock units (PSUs) vested and were settled in 2,714 shares of capital stock at $469.56 per share, with 1,192 shares withheld to cover tax obligations.
The vested PSUs tied to cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, yielding an award of 123% of target, or 124.1% of target including reinvested dividends. A separate PSU tranche based on relative total shareholder return over the same period earned 0% of target, even after dividend reinvestment.
McNamara also received a new grant of 5,114 PSUs that will vest based on performance targets over January 1, 2026 to December 31, 2028, with the performance level to be determined by March 15, 2029 and any earned shares delivered thereafter.
Chemed VP and Chief Legal Officer Brian C. Judkins reported performance stock unit activity and related share movements. On February 13, 2026, 351 shares of capital stock were acquired at $469.56 per share upon PSU vesting, with 102 shares withheld to cover taxes, leaving 2,436 shares directly owned.
Two PSU tranches of 283 units each were exercised, and Judkins then received a new award of 908 performance stock units, bringing his direct PSU holdings to 2,306 units. One PSU program based on cumulative adjusted EPS paid out at 123% of target (124.1% including dividends) after achieving $67.67 versus a $66.46 maximum threshold, while a separate total shareholder return PSU program paid out at 0% of target.
Chemed Corp. director Andrea R. Lindell reported a small change in ownership. On 12/26/2025, Lindell disposed of 463 shares of Chemed capital stock in a transaction coded "G," which indicates a gift. Following this transfer, Lindell beneficially owns 5,539 shares of Chemed stock, held directly. This filing simply updates public records of insider ownership for the company.
Chemed Corp. insider Kevin J. McNamara, who serves as director, president and CEO, reported a sale of company stock. On 11/24/2025, he sold 2,000 shares of Chemed capital stock in an open market transaction coded as "S" for sale. The weighted average sale price was $437.55 per share, with individual trade prices ranging from $436.13 to $438.53.
After this transaction, McNamara beneficially owns 94,197 shares of Chemed stock in direct form. He has indicated a willingness to provide detailed breakdowns of the number of shares sold at each separate price within the reported range to Chemed, its security holders, or SEC staff upon request.
Chemed Corp executive vice president reports small share transfer
Chemed Corp executive vice president Spencer S. Lee reported a change in ownership of company stock. On 11/19/2025, Lee disposed of 60 shares of Chemed Corp capital stock in a transaction coded "G," which typically denotes a gift or similar transfer, at a reported price of $0.00 per share. After this transaction, Lee beneficially owns 14,567 shares directly.
Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.
The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.
Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.
Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.
Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.
Chemed Corp (CHE) reported an insider equity award. Director and vice president Thomas C. Hutton filed a Form 4 showing a grant of 6,338 stock options on 10/21/2025, with an exercise price of $443.79 per share. The options relate to Chemed capital stock and expire on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following the reported transaction, Hutton beneficially owned 26,718 derivative securities. Ownership is reported as direct.
Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.